Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

U.K. investigators evaluate intravesical MeGLA in superficial bladder cancer patients

Feb. 25, 2002

ZD-0473 associated with manageable toxicity, activity in hormone-refractory prostate cancer

Feb. 25, 2002

Researchers at the University of Edinburgh synthesize anticancer ruthenium complexes

Feb. 22, 2002

Compounds for damaging newly formed vascular endothelium disclosed by Angiogene

Feb. 22, 2002

Zevalin therapeutic regimen approved for NHL

Feb. 22, 2002

First multiple-dose clinical study of ERA-923 in healthy postmenopausal women

Feb. 22, 2002

Inhibitors of cyclin-dependent kinases with potential as antitumor agents

Feb. 21, 2002

Casodex 150 mg receives priority review in early-stage prostate cancer

Feb. 21, 2002

Novel anticancer therapy target validated at Cell Therapeutics

Feb. 21, 2002

ImmunoGen and Millennium sign exclusive product license

Feb. 21, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...